University of New South Wales: The Altair Study

Project Timeline

November 2006 – November 2011

Antiretroviral therapy is complicated by drug interactions and contraindications. Novel regimens are needed.

This open label study randomly assigned treatment-naive, human immunodeficiency virus (HIV)—infected subjects to receive tenofovir-emtricitabine with efavirenz (Arm I), with ritonavir-boosted atazanavir (Arm II), or with zidovudine/abacavir (Arm III). Pair-wise comparisons of differences in time-weighted mean change from baseline plasma HIV-RNA to week 48 formed the primary analysis. Treatment arms were noninferior if the upper limit of the 95% confidence interval (CI) was <0.5 log10 copies/mL. Secondary objectives included virologic, immunologic and safety end points.

External Links

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment-Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study

Assessing site performance in the Altair study, a multinational clinical trial – BioMedCentral

Events

Other Clinical Research

Strategic Timing of Anti-Retroviral Treatment (START Study)

The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use...

Making Drug Treatment Work: Opportunities and Challenges Towards an Evidence and Rights-Based Approach

Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this...

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)

First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a...